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Abstract
The mechanisms underlying the Hepatitis C virus (HCV) resistance to interferon alpha (IFN-a) are not fully
understood. We used IFN-a resistant HCV replicon cell lines and an infectious HCV cell culture system to elucidate
the mechanisms of IFN-a resistance in cell culture. The IFN-a resistance mechanism of the replicon cells were
addressed by a complementation study that utilized the full-length plasmid clones of IFN-a receptor 1 (IFNAR1),
IFN-a receptor 2 (IFNAR2), Jak1, Tyk2, Stat1, Stat2 and the ISRE- luciferase reporter plasmid. We demonstrated that
the expression of the full-length IFNAR1 clone alone restored the defective Jak-Stat signaling as well as Stat1, Stat2
and Stat3 phosphorylation, nuclear translocation and antiviral response against HCV in all IFN-a resistant cell lines
(R-15, R-17 and R-24) used in this study. Moreover RT-PCR, Southern blotting and DNA sequence analysis revealed
that the cells from both R-15 and R-24 series of IFN-a resistant cells have 58 amino acid deletions in the
extracellular sub domain 1 (SD1) of IFNAR1. In addition, cells from the R-17 series have 50 amino acids deletion in
the sub domain 4 (SD4) of IFNAR1 protein leading to impaired activation of Tyk2 kinase. Using an infectious HCV
cell culture model we show here that viral replication in the infected Huh-7 cells is relatively resistant to
exogenous IFN-a. HCV infection itself induces defective Jak-Stat signaling and impairs Stat1 and Stat2
phosphorylation by down regulation of the cell surface expression of IFNAR1 through the endoplasmic reticulum
(ER) stress mechanisms. The results of this study suggest that expression of cell surface IFNAR1 is critical for the
response of HCV to exogenous IFN-a.
Keywords: Hepatitis C virus (HCV), Interferon alpha (IFN-α), Interferon alpha-receptor 1 (IFNAR1), Jak-Stat signaling,
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Introduction
Hepatitis C virus (HCV) is a positive-stranded RNA
virus that infects the liver. The majority of patients after
initial exposure to the virus develop a chronic infection.
Chronic HCV infection can gradually evolve into liver
cirrhosis, end stage liver diseases and hepatocellular car-
cinoma [1-3]. The standard treatment option of chronic
HCV infection is the combination of IFN-a and riba-
virin [4]. This therapy cures approximately 50% of
chronic HCV infections and the HCV in a majority of
chronically infected patients develop resistance. The
mechanism of IFN-a resistance in these patient popula-
tions is not fully understood. Understanding the IFN-a
resistance mechanism of HCV infection is important to
develop an alternative therapeutic strategy to clear the
infection.
To understand the mechanism of HCV resistance to
IFN-a, we have utilized stable replicon cell lines and the
infectious HCV cell culture model system. The replicon
cells express NS3 to NS5B protein required for replica-
tion of HCV sub-genomic RNA but they lack structural
proteins and do not produce infectious virus. We have
isolated nine stable IFN-a resistant Huh-7 based
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replicon cell lines (HCV1b) after long-term treatment
with IFN-a. We have shown that the replication of
HCV subgenomic RNA is totally resistant to IFN-a [5].
Each of nine IFN-a resistant Huh-7 replicon cells
showed reduced activation of pISRE-firefly luciferase
promoter and impaired phosphorylation of Stat proteins
[5-7]. All of the cured Huh-7 cell clones showed signifi-
cant reduction in the ISRE promoter activation and a
defect in the Jak-Stat signaling. Previously, we reported
that low level expression of Jak1 and Tyk2 kinases in
these IFN-a resistant cell lines. However, stable expres-
sion of either Jak1 or Tyk2 or both in resistant Huh-7
cells did not complement the defective Jak-Stat signaling
and antiviral response of IFN-a.
This current study was performed to elucidate the
mechanism of defective Jak-Stat signaling in the IFN-a
resistant replicon cell lines as well as infectious HCV
cell culture model. The ability of the individual proteins
of the Jak-Stat signaling pathway to overcome the
reduced IFN-a signaling and ISRE promoter activation
in replicon cell culture was examined by complementa-
tion. Expression of wild type IFNAR1 protein only com-
plemented the defective Jak-Stat signaling of resistant
replicon cell lines. The nuclear translocation of Stat1-
GFP, Stat2-GFP, Stat3-GFP and antiviral action of IFN-
a was restored in the resistant cells by stable expression
of IFNAR1 suggesting the existence of no additional
defects in the downstream Jak-Stat pathway. Reverse
transcription (RT) PCR and DNA sequence analysis of
IFNAR1 mRNA revealed that the defective Jak-Stat sig-
naling and IFN-a resistance was due to the expression
of a truncated version of IFNAR1 protein in all resistant
Huh-7 cell lines. The truncation in the SD1 and SD4
domains of IFNAR1 blocked the activation of Tyk2
kinase leading to the impaired phosphorylation of down-
stream Stat1 and Stat2 proteins and defective Jak-Stat
signaling. We also reported here that HCV infection
directly modulates the expression of IFNAR1 and cre-
ates defective Jak-Stat signaling and remains resistant to
IFN-a. Results of this in vitro study suggest that altered
expression of IFNAR1 leads to defective Jak-Sat signal-
ing and continued resistance to IFN-a in HCV cell cul-
ture model.
Materials and methods
Development of IFN-a sensitive and resistant HCV
replicon cell lines
Stable resistant replicon cells (HCV1b) were generated
in our laboratory by selecting cell clones that survived
IFN-a treatment as described previously [5]. Cured IFN-
a resistant Huh-7 cells were prepared from an indivi-
dual resistant replicon cell line by eliminating HCV
replication by repeated treatment with cyclosporine-A (1
μg/ml) as described previously [7]. An IFN-a sensitive
cured Huh-7 cell line (S-5/15) was prepared from 5-15
replicon cell line by eliminating HCV after IFN-a treat-
ment. Interferon sensitive and interferon resistant phe-
notypes of cured Huh-7 cells were examined by
measuring their ability to activate ISRE-firefly luciferase
promoter in the presence of exogenous IFN-a. All HCV
positive replicon cell lines were maintained in Dulbec-
co’s Modified Eagle’s Medium (DMEM) supplemented
with 2 mM L-glutamine, sodium pyruvate, nonessential
amino acids, 100 U/ml of penicillin, 100 mg/ml of strep-
tomycin and 5% fetal bovine serum supplemented with
the G-418 (1 mg/ml). The cured Huh-7 cell lines were
cultured in the same growth medium without the G-418
drug. A stable cell line expressing IFNAR1 was made by
electroporating the cDNA of full length IFNAR1 clone
in R-17/3 cells and selecting with DMEM containing G-
418 (250 μg/ml). Recombinant human IFN-a 2 b was
purchased from Schering Plough (Kenilworth, NJ, USA)
and IL-6 was obtained from Peprotech (RockyHill, NJ,
USA).
Western blot analysis and antibodies
Antibodies to Jak1, phospho Jak1 (Tyr1022/1023), Tyk2,
phospho Tyk2 (Tyr1054/1055), Stat1, phospho Stat1
(Tyr701), Stat2, phospho Stat2 (Tyr690), Stat3, phospho
Stat3 (Tyr705), IRE1-a, BiP, PERK, phospho eIF2-a and
beta actin were purchased from Cell Signaling (Beverly,
MA, USA). The antibody to IFNAR1 and IFNAR2 was
obtained from Santa Cruz Biotechnology (Santa Crutz,
CA, USA). The monoclonal antibody to HCV core was
obtained from Thermo Scientific, Rockford, IL, USA.
Western blotting was performed using a standard proto-
col established in our laboratory. Briefly IFN-a treated
or untreated Huh-7 cells cultured in a 6-well plate were
lysed with 200 μl of RIPA buffer (150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM
Tris, pH 8.0) supplemented with protease inhibitors
(Thermo Scientific, Rockford, IL, USA) and phosphatase
inhibitor cocktail (Roche Diagnostics GmbH, Man-
nheim, Germany). Total protein in the lysate was quan-
tified using BioRad protein assay kit (BioRad, Hercules,
CA, USA). Then equal amount of protein lysates from
each sample was mixed in SDS-loading buffers. Proteins
were separated by NuPAGE 4-12% gel and then trans-
ferred onto a nitrocellulose membrane (GE healthcare,
Buckinghamshire, UK). The membrane was blocked
with 5% fat-free milk powder in 50 mM TBS pH 7.6
with 0.1% Tween 20 (TBS-Tw20) at room temperature
for 1 hour. The membrane was washed three times and
incubated overnight at 4°C with a primary antibody
diluted in TBS-Tw20 containing 5% fat-free milk pow-
der. After this step, the membrane was washed three
times with TBS-Tw20 and reacted for one hour with
secondary antibody (either anti-rabbit or anti-mouse
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supplied in the ECL kit) conjugated with horseradish
peroxidase (HRP) at a dilution of 1:2000. Bound antibo-
dies were detected using the ECL Plus Western blotting
detection system (GE healthcare, Buckinghamshire, UK)
and chemiluminiscent signals were detected using high
performance chemiluminescence film (GE healthcare,
Buckinghamshire, UK).
Flow cytometry
The flow analysis of all the nine cured IFN-a resistant
cells and cured IFN-a sensitive cells was carried out by
using a rabbit monoclonal antibody targeted to the C-
terminus of IFNAR1 (Epitomics, Burlingame, CA, USA).
The protocol used is as described earlier [6] with slight
modification.
Complementation studies
The contribution of each Jak-Stat protein to the
mechanisms of IFN-a resistance was examined by
complementation studies. The human IFNAR1 and
three different IFNAR2 cDNA clones were purchased
from OriGene Technologies (Rockville, MD, USA) and
from our collaborator [8]. The cDNA clone of human
Tyk2 was kindly provided by Sandra Pellegrini, France
[9] and also from the laboratory of John J Krolewski,
Columbia University, New York, USA [10]. The full-
length cDNA clone of human Jak1 was obtained from
the laboratory of Ketty Chou, Roswell Park Cancer
Institute, Buffalo, New York, USA [11]. The cDNA
clones of human Stat1 and Stat2 GFP were described
earlier [12]. Stat3-GFP plasmid was obtained from Ori-
Gene Technologies (Rockville, MD, USA). The plasmid
pISRE-Luc containing four tandem copies of the 9-27
ISRE positioned directly upstream of the HSV-1TK
TATA box, driving the firefly luciferase gene was
kindly provided by Steve Goodbourn, St George’s Hos-
pital and Medical School, University of London, Lon-
don, UK [13]. Cured interferon sensitive and resistant
Huh-7 cells were plated in 12-well tissue culture
dishes. The next day they were transfected with 0.5 μg
of ISRE-firefly luciferase plasmid, 0.5 μg of control
Renilla luciferase plasmid (pRL-TK) and 1 μg of indivi-
dual cDNA expression plasmid using the FuGene6
transfection reagent (Roche Diagnostic Corporation,
Indianapolis, IN, USA). IFN-a 2 b (1000 IU/ml) was
added after the transfection step to examine which
Jak-Stat proteins complement the ISRE-mediated acti-
vation of the luciferase gene. After 24 hours, cells were
treated with a reporter lysis buffer (Promega Madison,
WI) according to the manufacturer’s instruction. An
equal amount of protein extracts (20 μl) was mixed
with 100 μl of substrate buffer and luciferase activity
was measured by integrating the total light emission
over ten second interval in a luminometer (Luman
LB9507; EG & G Berthold, Berlin, Germany). The level
of luciferase expression in the Huh-7 cells transfected
with ISRE promoter was measured with or without
IFN-a treatment. The consistency of the results was
checked by the repetition of each experiment three
times.
Nuclear translocation of Stat-GFP fusion proteins
Cured resistant (R-17/1) and cured sensitive Huh-7 cells
(S-5/15) were plated in a two well Lab-Tek chamber
slide (Electron Microcopy Sciences, Hatfield, PA, USA)
at a density of 5 × 104 cells per ml. Twenty-four hours
later, the cells were transfected with 1 μg of the indivi-
dual STAT-GFP plasmid (Stat1-GFP, Stat2-GFP and
Stat3-GFP). At 48 hours post-transfection To-Pro3
nuclear marker (Invitrogen, Molecular Probes, Oregon,
USA) was added to the samples at 1 μg/ml and incu-
bated for five minutes in PBS. IFN-a (1000 IU/ml) was
then added to the appropriate groups. Confocal micro-
scopy was performed using a Leica TCS SP2 confocal
microscope equipped with three lasers (Leica Microsys-
tems, Exton, PA). Optical slices were collected at 512 ×
512 pixel resolution. NIH Image version 1.62 and Adobe
Photoshop version 7.0 were used to assign correct colors
of channels collected, including the Green Fluorescent
Protein (green), To-Pro3 633 (far red).
Ribonuclease protection assay (RPA)
Total RNA was isolated from the JFH1-GFP RNA trans-
fected Huh-7 cells by the GITC method and subjected
to RPA for HCV positive-strand RNA using an anti-
sense RNA probe targeted to the 5’ UTR as described
previously [6]. The same amounts of the RNA extracts
were subjected to RPA for GAPDH mRNA. We used a
linearized pTRI-GAPDH-human anti-sense control tem-
plate to prepare a probe to detect GAPDH mRNA using
Sp6 RNA polymerase (Ambion Inc., Austin, TX, USA).
The appearance of a 218-nt fragment in the RPA indi-
cated the presence of positive-strand HCV RNA.
RT-PCR and DNA sequencing of full-length IFNAR1
Total RNA was isolated from IFN-a sensitive and resis-
tant cultured Huh-7 cells by the GITC method. The
RNA pellet was resuspended in nuclease free water,
quantified by a spectrophotometer and stored at -70°C
in several aliqouts. Two separate DNA fragments (F1
and F2) covering the full-length IFNAR1 mRNA was
amplified from the RNA extracts of cultured Huh-7
cells by RT-PCR (14-16). The first 949 bp fragment (F1)
starting from nucleotides 83 to 1032 was amplified
using a sense primer (IFNAR1/83/S 5’-ATGGCGGCT-
GAGAGGAGCTG-3’) and antisense primer (IFNAR1/
1032/AS 5’-TTGAGGAAAGACACACTGGGTA-3’).
The amplified DNA was confirmed by Southern blot
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analysis using an internal oligonucleotide probe
(IFNAR1/Probe/253 5’-GTAGAGGTCGACATCATA-
GATGACAACTTTATCCTGAGGT-3). Likewise, the
second 1025 bp fragment (F2) starting from nucleotides
901 to 1926 was amplified using the sense primer
(IFNAR1/901/S 5’-TATGCAAACATGACCTTTCAAG-
3’) and antisense primer (IFNAR1/1926/AS 5’-ACAGG-
GAAACGTCCTCTCTGTAGTT-3’). The PCR amplified
DNA was confirmed by Southern blotting using a probe
(IFNAR1 Probe/1633 5’-GAGGAACAAATCGAAAA
ATGTTTCATAGAAAATATA-3’). The RT-PCR reac-
tion of each fragment was carried out using a standard
method established in our laboratory. Briefly, an aliquot
of 2 μg of total RNA was incubated with 500 ng of anti-
sense primer and incubated at 65°C for 10 minutes fol-
lowed by immediate chilling on ice. This template
primer mix was subsequently incubated with 10 units of
AMV reverse transcriptase (RT) (Promega, Madison,
WI, USA), 1.5 mM MgCl2, 1 mM dNTP mix, 40 units
RNaseOut (Invitrogen, Carlsbad, CA, USA) in a total of
20 μl reaction volume for 90 minutes at 42°C. Identical
reaction without the addition of RT enzyme were used
as controls. PCR amplification was carried out using 5
μl of the cDNA products along with 5 unit GoTaq Flexi
DNA polymerase in 1X polymerase buffer (Promega,
Madison, WI, USA), 200 μM of dNTP mix, 1.5 mM
MgCl2, 250 ng of sense and antisense primer in a 50 μl
total reaction volume. PCR amplification was carried
out for 3 minutes of incubation at 95°C followed by 45
cycles of 30 seconds at 95°C, 30 seconds at 55°C, 1 min-
ute at 72°C, followed by a final 10-minute extension at
72°C. The PCR products were resolved on a 1.5% agar-
ose gel along with 100-bp DNA ladder stained with ethi-
dium bromide, visualized under UV transilluminator
and photographed (Fuji Film, Japan). The specificity of
the PCR amplified DNA was confirmed by Southern
blot analysis using 32P-labeled oligoprobe specific for
IFNAR1 sequences (NM_000629) [14]. The PCR pro-
ducts were then run on an agarose gel and purified.
DNA sequence analysis was performed at Genewiz Inc,
NJ, USA using the sense and antisense primers. The
sequences were analyzed using BioEdit Sequence Align-
ment Editor version 7.0.4.1 software.
IFN-a treatment and the infectious HCV cell culture
system
An infectivity assay for HCV was performed using a
published protocol [6]. HCV infected Huh-7 cells were
treated with an increasing concentration of IFN-a
(Intron A, Schering-Plough, NJ, USA). The antiviral
effect of IFN-a against HCV was confirmed by obser-
ving GFP expression by fluorescence microscopy, Wes-
tern blot for core and HCV RNA level by real-time RT-
PCR and Southern blot analysis. The real-time RT-PCR
was done according to our previous publication [6] and
some modifications according to Zhu et al [15]. The
southern blot analysis was performed according to
Akyol et al [16].
Results
Defective Jak-Stat signaling in IFN-a resistant replicon
cells
To understand the contribution of the virus and host
cellular factors in the mechanisms of IFN-a resistance,
we first used stable Huh-7 cell lines replicating sub-
genomic HCV RNA as a model system. Figure 1 pro-
vides an overview of the development of IFN-a resistant
replicon Huh-7 cell lines with or without HCV. Nine
stable cell lines replicating HCV 1 b replicon RNA were
isolated. The role of the viral factors in the mechanism
of resistance in replicon cells were excluded because
reduced activation of the ISRE promoter was also
observed in all cured Huh-7 cell lines, even after elimi-
nating HCV RNA replication by cyclosporine A. These
results led us to suspect that altered expression of inter-
feron induced Jak-Stat signaling is the cause of low ISRE
promoter activation and IFN-a resistance. To establish
the mechanisms of the defective Jak-Stat signaling, the
expression levels of Jak-Stat signaling molecules in resis-
tant replicon cell lines were examined in a representa-
tive IFN-a sensitive (S-5/15) and an IFN-a resistant cell
line (R-17/3) by Western blot analysis using antibodies
targeted to the phosphorylated and non-phosphorylated
form of Jak1, Tyk2, Stat1 and Stat2 (Figure 2A). It was
consistently observed that the phosphorylation of Jak1,
Tyk2, Stat1 and Stat2 proteins were completely blocked
in R-17/3 cells after IFN-a treatment. Expression levels
of total Jak1, Tyk2, Stat1 and Stat2 proteins between the
sensitive and resistant Huh-7 cells were not different.
Since the expression level of the cell surface receptors
(IFNAR1 and IFNAR2) is critical for the IFN-a induced
signaling events leading to the phosphorylation of the
Jak-Stat proteins, the expression levels of IFNAR1 and
IFNAR2 proteins in cured sensitive and resistant Huh-7
cells were measured by Western blot analysis and found
to be not significantly different (Figure 2A). The
IFNAR1 expression level was also examined using pro-
tein lysates prepared from nine different IFN-a resistant
Huh-7 cell lines. We detected the ~100-110 kD mature
form of IFNAR1 and 90 kD IFNAR2 in all resistant
Huh-7 cell lines at levels comparable to those in S-5/15
cells (Figure 2B). The endogenous expression level of
IFNAR1 between the cured S-5/15 and cured resistant
Huh-7 cell lines was also examined by flow analysis
using a monoclonal antibody (Figure 3). Although there
were slight variations in the percentage of IFNAR1 posi-
tivity between the resistant and sensitive Huh-7 cells by
flow analysis, these differences were not significant.
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It is known that the type I IFN receptor and the
type II IFN receptor consist of two distinct subunits:
IFNAR1 and IFNAR1 for type I receptor and IFNGR1
and IFNGR2 for the type II receptor. In the case of
the type I IFN receptor, the IFNAR1 subunit is con-
stitutively associated with tyrosine kinase 2 (Tyk2),
whereas in the case of the type II IFN receptor, the
IFNGR1 subunit is associated with Jak1. The first step
in both the type I and Type II IFN-mediated signaling
is the activation of these receptor-associated kinases
leading to a ligand-dependent rearrangement and
dimerization of the receptor subunits followed by
autophosphorylation and activation of the receptor
associated kinases [17]. To characterize the biochem-
ical interactions that impede the Stat phosphorylation
and cellular Jak-Stat signaling in the resistant Huh-7
cells, we examined the phosphorylation of Tyk2 and
Jak1 kinases after they were treated with either IFN-a
or IFN-g. We found IFN-a dependent phosphoryla-
tion of the Jak1 and Tyk2 and IFN-g dependent phos-
phorylation of Jak1 protein in sensitive Huh-7 cells
(S-5/15) (Figure 4). When a similar experiment was
performed using a resistant cell line R-17/3, we found
that only the IFN-a induced phosphorylation of Jak1
and Tyk2 are blocked in these cells (Figure 4). There
was no difference in the IFN-g dependent phosphory-
lation of Jak1 in the resistant Huh-7 cells. These data
suggest that the IFN-a dependent activation of Tyk2
and Jak1 is blocked in the resistant Huh-7 cells (R-
17/3) cells.
Figure 1 Schematic diagram showing the isolation of IFN-a resistant and sensitive replicon cell lines. Three different HCV 1 b sub-
genomic replicon cell lines (Con-15, Con-17 and Con-24) with low ISRE-luciferase activity were cultured in growth media supplemented with G-
418 (1 mg/ml) and IFN-a 2 b for more than 4 weeks. Resistant cell colonies that survived the IFN-a 2 b treatment were picked and stable
resistant cell lines (R-15, R-17 and R-24 series) were established. Cured Huh-7 cell line from each replicon was prepared by repeated treatment
with cyclosporine A (1 μg/ml). All of the cured Huh-7 cells were free from HCV and still maintained low level ISRE-luciferase activity after IFN-a 2
b treatment. 5/15 cell line is IFN-a sensitive HCV 1 b replicon cell line. HCV replication in this cell line was eliminated by IFN-a 2 b and used as
the positive control.
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Figure 2 Western blot analysis of Jak-Stat signaling between S-5/15 and R-17/3 cell line. An equal number of S-5/15 and R-17/3 Huh-7
cells were treated with IFN-a 2 b (1000 IU/ml). Cells were harvested at different time intervals (in hrs) by trypsin-EDTA treatment, washed in PBS.
Western blot analysis was performed using antibodies to IFNAR1, IFNAR2, pJak1, Jak1, pTyk2, Tyk2, pStat1, Stat1, pStat2, Stat2 and b-actin and
then blots were developed by ECL kit. (A) Expression level of Jak-Stat proteins between the two cell lines. Left panel shows the expression of
Jak-Stat signaling proteins in the IFN-a sensitive Huh-7 cell line (S-5/15). Right panel shows the expression of Jak-Stat signaling proteins in the
IFN-a resistant Huh-7 cell line (R-17/3). The level of b-actin protein in the blot indicated that equal amounts of protein lysate were loaded onto
the gel in the Western analysis. (B) Show the expression of fully glycosylated mature form of IFNAR1 (~100 kD) and IFNAR2 (~90 kD) in all nine
of different IFN-a resistant cell lines and one sensitive Huh-7 cell line (S-5/15) by Western blot analysis.
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Expression of wild-type IFNAR1 overcomes defective Jak-
Stat signaling in resistant Huh-7 cell lines
The role of the individual components of the Jak-Stat
signaling proteins in the mechanisms of IFN-a resis-
tance was examined by complementation studies using
ISRE-firefly luciferase plasmid and plasmid clones of
IFNAR1, IFNAR2a, IFNAR2b, IFNAR2c, Jak1, Tyk2,
Stat1 and Stat2. The results of these experiments are
summarized in Figure 5A, B and 5C. IFN-a induced
ISRE-luciferase activity did not change in R-17/3 Huh-7
cells when it was transfected with individual plasmid
cDNA clones for expression of Stat1, Stat2, Jak1 and
Tyk2 with or without IFN-a treatment. Interestingly, a
significant increase of ISRE-firefly luciferase activity in
the cured R-17/3 cells by IFN-a was seen after transfec-
tion with full-length cDNA of IFNAR1 (Figure 5A). The
induction level of ISRE-luciferase by IFN-a in the R-17/
3 cells was comparable to the S-5/15 cells, suggesting
that the full-length IFNAR1 was able to rescue the
defective Jak-Stat signaling. It is known that there is one
isoform of IFNAR1 and three isoforms of IFNAR2
expressed in normal human cells [18]. The contribution
Figure 3 Flow cytometry of IFNAR1 expression in IFN-a resistant Huh-7 cells. Flow cytomeric analysis demonstrating expression of full-
length mature IFNAR1 between the sensitive Huh-7 line (S-5/15) and nine different alpha resistant Huh-7 cell lines using a rabbit monoclonal
antibody targeting to the C-terminus of human IFNAR1 at a dilution of 1:50. The secondary antibody used is anti rabbit IgG Alexa Fluor 488 at a
dilution of 1:1000 (Invitrogen, Oregon, USA). The % of positive cells was shown for each cell line.
Figure 4 IFN-a dependent activation of Tyk2 and Jak1 is prevented in resistant Huh-7 cells. Cured S-5/15 and R-17/3 cells were treated
with IFN-a 2 b (1000 IU/ml) or IFN-g (1000 IU/ml) for different time intervals 10, 30 and 60 minutes and cell lysates were examined for Jak1 and
Tyk2 phosphorylation by Western blot analysis. Left panel shows the time dependent phosphorylation of Jak1 and Tyk2 kinases in sensitive Huh-
7 cells (S-5/15) by IFN-a and IFN- g (1000 IU/ml). Right panel shows the phosphorylation of Jak1 and not Tyk2 in resistant Huh-7 cells (R-17/3) by
IFN-a and IFN-g (1000 IU/ml). b-actin levels are the same among the protein samples analyzed.
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of the three different variants of IFNAR2 clones in over-
coming the defective Jak-Stat signaling and ISRE promo-
ter activation was examined. Expression of none of the
IFNAR2 variants modulated the ISRE-luciferase promo-
ter activity in the R-17/3 cells (Figure 5B). The ability of
the IFNAR1 clone alone, complementing the defective
Jak-Stat signaling of R-17/3, has prompted us to test
whether it can also activate the ISRE promoter in other
IFN-a resistant Huh-7 cell lines. Nine different IFN-a
resistant cell lines and one sensitive Huh-7 cell line
Figure 5 IFNAR1 protein expression complements the ISRE-firefly luciferase promoter activation in the resistant Huh-7 cells. The cured
resistant Huh-7 cell line (R-17/3) was co-transfected with ISRE-firefly luciferase plasmid along with each expression plasmid by FuGene6
transfection reagent. The pRL-TK plasmid was used as a transfection control. After this step, cells were treated with IFN-a (1000 IU/ml). After 24
hours, cells were lyzed and luciferase activity was measured. The graphs represent a relative to control luciferase activity. (A) The activation of
ISRE promoter by IFN-a in R-17/3 cells expressing different proteins of Jak-Stat signaling expressed as relative luciferase units (RLU) between IFN-
a treated and untreated. Expression of wild type full-length IFNAR1 protein is able to induce the ISRE-Luciferase activity. (B) The induction of
ISRE-luciferase activity in the R-17/3 cells by IFN-a in the presence of three different variants of IFNAR2 and wild type IFNAR1 was depicted as
fold increase as compared to untreated cells. (C) IFN-a induces the ISRE-Firefly luciferase activity (fold increase) in all nine IFN-a resistant Huh-7
cell lines when they were co-transfected with the wild type IFNAR1 plasmid.
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(S-5/15) were co-transfected with IFNAR1 and pISRE-
firefly luciferase plasmid. The activation of ISRE-firefly
luciferase after IFN-a treatment was measured after 24
hours. In these experiments, the fold induction of the
ISRE-luciferase activity in each resistant cell line due to
IFN-a treatment was measured. Expression of the
IFNAR1 alone overcomes the defective Jak-Stat signaling
in all resistant Huh-7 cell clones (Figure 5C).
Stable expression of IFNAR1 overcomes impaired
phosphorylation, nuclear translocation of Stat and
antiviral response to IFN-a
We clarified whether or not stable expression of
IFNAR1 in the resistant cells could also improve the
down-stream Jak-Stat signaling, and Stat phosphoryla-
tion and nuclear translocation. Cured R-17/3 cells were
stably transfected with IFNAR1 and selected with G-418
(250 μg/ml). IFN-a induced Stat1 and Stat2 phosphory-
lation in the resistant Huh-7 cell line (R-17/3), sensitive
Huh-7 cell line (S-5/15) and stable IFNAR1 transfected
R-17/3 resistant Huh-7 cell line were examined in a
kinetic study by Western blotting. Phosphorylation of
Stat1, Stat2 and Stat3 proteins were induced by IFN-a
treatment only in S-5/15, but not in R-17/3 Huh-7 cells.
Stable expression of IFNAR1 in the resistant R-17/3 cell
clone restored the phosphorylation of Stat1, Stat2 and
Stat3 proteins (Figure 6A). The defective Jak-Stat signal-
ing due to functional inactivation of IFNAR1 did not
affect the phosphorylation of Stat1 and Stat3 in the
resistant Huh-7 cells after treatment with IL-6 (Figure
6B). However, we noticed there was an increase in the
Stat3 phosphorylation by IL-6 in sensitive S-5/15 or in
R-17/3 cells with a stable expression of IFNAR1. The
impact of restoring the Stat phosphorylation on the
nuclear translocation of Stat1, Stat2 and Stat3 protein
was examined using chimeric clones of Stat and green
fluorescence proteins (Stat1-GFP, Stat2-GFP and Stat3-
GFP) in a transient transfection experiment. Results of
these experiments suggest that Stat1-GFP, Stat2-GFP
and Stat3-GFP proteins efficiently localized to the
nucleus of S-5/15 cells after IFN-a treatment (Figure 7).
However, Stat1-GFP, Stat2-GFP and Stat3-GFP proteins
were localized in the cytoplasm and their nuclear trans-
location after IFN-a treatment was blocked in the R-17/
3 cells. The stable expression of IFNAR1 in the resistant
cells corrected the impaired nuclear translocation of
Stat1-GFP, Stat2-GFP and Stat3-GFP protein.
We also examined whether the stable expression of
IFNAR1 in the resistant cells could improve the antiviral
action of IFN-a against HCV replication. Three different
cured Huh-7 cells were transfected with in vitro tran-
scribed full-length HCV-GFP RNA (JFH1-GFP) by the
electroporation method described previously [6]. After
24 hours, transfected cells were cultured in a medium
containing IFN-a (1000 IU/ml). Positive strand HCV-
RNA levels in the transfected Huh-7 cells were mea-
sured by RPA assay after 72 hours. The presence of 218
nucleotide protected fragment in all three Huh-7 cells
lines suggested that replication of full-length HCV-GFP
RNA has occurred in all three Huh-7 cell lines at 72
hours after transfection. The results of RPA assay indi-
cate that stable expression of the IFNAR1 in the resis-
tant Huh-7 cells made HCV replication sensitive to
IFN-a (Figure 8A). The antiviral effect of IFN-a against
full-length HCV RNA replication was also measured by
comparing cytoplasmic HCV-GFP expression in Huh-7
cells with and without IFN-a treatment after 72 hours.
IFN-a effectively inhibits HCV replication in sensitive S-
5/15 but not in R-17/3 cells (Figure 8B). HCV-GFP
expression was inhibited in R-17/3 cells after stable
expression of IFNAR1. IFN-a only inhibits HCV RNA
replication in the S-5/15 cell line and R-17/3 cell line
stable expressing IFNAR1. HCV RNA replication is not
inhibited in R-17/3 cells with the defective IFNAR1
expression.
All resistant Huh-7 cell lines show expression of truncated
IFNAR1
Total RNA was isolated from sensitive (S-5/15) and
three resistant (R-15/1, R-17/1 and R-24/1) Huh-7 cell
clones and the mRNA level of IFNAR1 was examined
by real-time RT-PCR. No differences were observed in
the level of mRNA using the primer sets targeted to the
N-terminal region of IFNAR1 (data not shown). We
then used RT-PCR based assay to amplify the full-length
mRNA of IFNAR1 in all resistant Huh-7 cell lines (Fig-
ure 9A). The full-length IFNAR1 in each resistant Huh-
7 cell lines was amplified into two fragments (F1 and
F2) using four sets of overlapping primers (Figure 9A).
The RT-PCR amplified DNA was confirmed by South-
ern blotting (data not shown). The sequence of PCR
amplified full-length IFNAR1 between sensitive (S-5/15)
and nine different resistant Huh-7 cell lines analyzed by
using web-based computer software (BioEdit Sequence
Alignment Editor Version 7.0.4.1). The DNA sequence
comparison of IFNAR1 mRNA between the S-5/15 cell
line and one resistant Huh-7 cell clone of R-15, R-17
and R-24 series (Figure 9B). This suggested that 5’trun-
cation of IFNAR1 protein in R-15 and R-24 series com-
pared to 3’truncation of extracellular domain of IFNAR1
in R-17/3 cells. IFNAR1 (557 aa) consists of an extracel-
lular domain (436 amino acids), a hydrophobic trans-
membrane domain of 21 amino acids and a C-terminal
intracytoplasmic domain of 100 amino acids [17-19].
The extracellular domain of IFNAR1 consists of four Ig-
like sub-domains (SDs) essential for ligand binding and
receptor assembly on the cell surface. The R-15 and R-
24 series IFN-a resistant replicon cell lines have a
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deletion of 58 amino acids (68-125 aa), (SD1 domain)
while the R-17 series resistant replicon line showed
deletion of 50 amino acids (382-431aa) (SD4 domain).
HCV replication in the infected cell culture is resistant to
IFN-a
Additional experiments were performed to rule out the
possibilities that the resistant phenotype of the replicon
cells could be due to an artifact of dual selection of IFN
and G418. The findings of HCV resistance to IFN in
replicon cell culture was confirmed by using more rele-
vant model of persistently infected full-length HCV in
cell culture. Cured S-5/15 cells were infected with a
HCV JFH1-GFP chimera virus as described earlier [6].
After 96 hours, infected cells were treated with different
concentrations of IFN-a (10-1000 IU/ml) for 72 hours.
Figure 6 Stable expression of IFNAR1 restored the phosphorylation Stat proteins in the cured resistant Huh-7 cell line (R-17/3). The
cured Huh-7 cell line (S-5/15) and (R-17/3) in culture were treated either with IFN-a 2 b (1000 IU/ml) or IL6 (50 ng/ml) and cells were harvested
after 30 and 60 minutes. Ten micrograms of protein lysate was run on a NuPAGE 4-12% gel and immunoblotting was used to determine pStat1,
pStat2 and pStat3 levels. (A) Phosphorylation of Stat1, Stat2 and Stat3 proteins in the sensitive and resistant Huh-7 cells. Left panel shows that
IFN-a induced phosphorylation Stat1, Stat2, Stat3 proteins in S-5/15 cells. Middle panel shows the lack of phosphorylation of Stat1 and Stat2 in
the R-17/3 cell line after treatment with IFN-a. Right panel shows that the stable transfection of R-17/3 cells with IFNAR1 restores the Stat1 and
Stat2 phosphorylation by IFN-a treatment. Total Stat1 and Stat2 levels were indistinguishable. (B) Shows that IL-6 induced phosphorylation of
Stat1 and Stat3 in Jak-Stat sensitive and defective Huh-7 cells.
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Figure 7 Confocal microscopy showing the nuclear translocation of Stat1, Stat2 and Stat3-GFP in sensitive and resistant Huh-7 cells
after IFN-a treatment. IFN-sensitive (S-5/15) and IFN-resistant (R-17/3)) cells were transfected with plasmid containing the Stat1-GFP, Stat2-GFP
or Stat3-GFP. IFN-a 2 b (1000 IU/ml) was added after 48-hours of transfection and images were captured after 30 minutes of treatment. The
nuclear translocation of each STAT-GFP construct with or without IFN-a treatment in the sensitive and resistant cells was examined under a
confocal microscope. The images are represented as the superimposition of Green Fluorescent Protein (green), To-Pro3 633 (far red).
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Results shown in Figure 10A indicate that GFP expres-
sion was not completely inhibited after IFN-a treatment.
Western blot analysis of HCV core protein confirmed
the incomplete antiviral response of IFN-a treatment
(Figure 10B). The intracellular HCV RNA content in the
infected cell culture after IFN-a treatment was also
measured by a real-time RT-PCR assay (Figure 10C)
indicating that the levels of HCV RNA did not decrease
in a dose dependent manner. The levels of HCV in the
infected cell culture receiving continuous IFN-a
Figure 8 Stable expression of IFNAR1 improves the antiviral response of IFN-a in resistant R-17/3 cells. Cured Huh-7 cells prepared from
S-5/15 and R-17/3 cells were transfected with full-length JFH1-GFP chimeric HCV RNA by electroporation. After 72 hours, these cells were treated
with IFN-a (1000 IU/ml) for an additional 72 hours. Replication of HCV in the transfected cells was examined by GFP expression and positive-
strand HCV-RNA was detected by RPA using a probe targeted to the highly conserved 5’UTR. (A) HCV RNA levels before and after IFN-a
treatment was measured by RPA. Left panel shows that high level HCV RNA replication in different Huh-7 clones without IFN-a treatment. Right
panel shows the HCV RNA level in the same set of Huh-7 cell lines after IFN-a treatment. IFN-a inhibits the level of HCV RNA in IFN-a sensitive
Huh-7 cells, but not in the resistant Huh-7 cell line. The antiviral effect of IFN-a can be restored upon stable expression of IFNAR1 in the resistant
Huh-7 cell line. The GAPDH mRNA levels served as controls. (B) Expression and replication of HCV-GFP in the transfected Huh-7 cells before and
after IFN-a treatment was measured by fluorescence microscopy at 20X magnification. The upper panel shows the expression HCV-GFP chimera
protein in different Huh-7 cell lines transfected with HCV without IFN-a treatment. The lower panel shows the expression HCV-GFP in the same
set of Huh-7 cells after IFN-a treatment. Positive expression indicates the impaired antiviral effect of IFN-a against HCV.
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treatment over two passages were examined by more
sensitive assays like RT-nested PCR followed by South-
ern blot analysis (Figure 10D). No significant change in
the intensity of Southern blot signal between the
untreated and treated samples was observed, thus con-
firming that HCV replication in the infected cell culture
is not inhibited completely by IFN-a.
HCV infection down regulates IFNAR1 expression and Jak-
Stat signaling
To understand the mechanism by which HCV replica-
tion in the infected cells develop resistance to IFN-a,
the expression level of IFNAR1 in cured S-5/15 Huh-7
cells was examined by Western blot and flow analysis
over time after HCV JFH1-GFP infection. Protein lysates
of HCV infected cells were examined for IFNAR1 levels
by Western blot analysis. Expression of functional
IFNAR1 (~100-110 kD) is down regulated after HCV
infection over time (Figure 11A). The decrease in the
IFNAR1 level correlates well with the increase in the
HCV core protein expression in the same lysates,
whereas the beta actin level remained unaltered. The
result of these Western blot analyses were also verified
by flow cytometric analysis using a rabbit monoclonal
antibody that detects the surface expression of IFNAR1
(Figure 11B). There was a significant decrease in the cell
surface expression of IFNAR1 (92% to 5%) over a 10-
day period in the HCV infected cured S-5/15 cells.
Figure 9 Schematic diagram and sequence analysis of open reading frame of human IFNAR1 by RT-PCR from the S-5/15 and R-15/1,
R-17/1 and R-24/1 cells. (A) Location of sense and antisense primers used for RT-PCR analysis of IFNAR1 coding sequence. The human IFNAR1
protein is 557 amino acids long that consist of an N-terminal extracellular cytokine-binding (EC) domain (436 aa), a hydrophobic transmembrane
(TM) domain (21 aa), and C-terminal intracytoplasmic (IC) domain (100 aa). F1 and F2 are the two PCR fragments amplified for final overlapping
PCR of full-length IFNAR1. (B) The amino acid sequence of IFNAR1 of S-5/15 cells perfectly matches with the reference wild type sequence of
IFNAR1 m RNA (Accession no- NM_000629). The R-15 and R-24 series resistant Huh-7 clone show an N-terminal deletion of 58 amino acids
starting from 68 aa to 125 aa in the IFNAR1. The R-17 series resistant Huh-7 cell clones show deletion of 50 amino acids staring from 382aa to
431 aa in the SD4 domain of IFNAR1. The dotted line indicates the deletion portion in the sequence.
Datta et al. Virology Journal 2011, 8:351
http://www.virologyj.com/content/8/1/351
Page 13 of 18
These results confirm that HCV infection itself down
regulates the cell surface expression of IFNAR1. The
down-regulated expression of IFNAR1 in the infected
cells impaired the phosphorylation of Stat1 and Stat2
proteins measured by Western blot analysis (Figure
11C). Using IFN-b promoter luciferase reporter plasmid,
we observed that HCV infection showed a time depen-
dent reduction of ISRE-luciferase promoter activity (Fig-
ure 11D). A previous study by Liu et al [20] reported
that full-length HCV replication created an unfolded
protein response (UPR), that downregulates the expres-
sion of IFNAR1. Therefore, the ER stress responses of
HCV JFH1-GFP replication in the cured S-5/15 cells
were measured by Western blot analysis. An increase in
IRE1a, BiP, PERK and phospho eIF2-a levels in the
HCV infected Huh-7 cells is clearly observed (Figure
11E). These results are in agreement with the fact that
HCV infection itself triggers ER stress response and
down regulate the expression of IFNAR1. These results
now partially account for the mechanisms by which
HCV replication in the infected cell culture is resistant
to IFN-a.
Discussion
The standard treatment for chronic HCV infection is
IFN-a and ribavirin. The majority of patients do not
respond to this treatment. The molecular mechanisms
as to why certain groups of chronic HCV patients
respond well to this treatment while others do not are
unclear. The low response rate to IFN-a has been
ascribed to a combination effect of viral and host related
factors [21,22]. To understand the viral and host cellular
factor contributing to IFN-a resistance, we have devel-
oped stable replicon cell lines that are sensitive and
resistant to IFN-a. In the replicon based cell culture
model, the viral protein NS3 to NS5B does not appear
to be responsible for blocking the IFN-a antiviral
response. Each of nine IFN-a resistant Huh-7 cell lines
have defective Jak-Stat signaling even after eliminating
HCV sub-genomic RNA. Phosphorylation of Jak1, Tyk2,
Stat1, Stat2 and Stat3 protein was blocked in resistant
Huh-7 cell lines, but not in the sensitive Huh-7 cells.
The impaired phosphorylation of Jak1, Tyk2 and Stat
proteins in the resistant Huh-7 cells are not caused by a
low-level expression IFNAR1 or degradation of IFNAR1
Figure 10 HCV replication in the infected cell culture is resistant to IFN-a. Huh-7 cells were treated with different doses IFN-a 2 b (1000
IU/ml)96 hrs after HCV infection. (A) After 72 hours of treatment HCV levels in the infected cells were examined for HCV-GFP expression under a
fluorescence microscope. (B) HCV core protein detection by Western blot analysis and b-actin as loading control. (C) HCV mRNA detection by
real-time RT-PCR after IFN-a 2 b treatment with different doses. The HCV mRNA was expressed as log copies per μg of cellular RNA. The dotted
line indicates the detection limit of the assay. (D) HCV RNA detection in the multicycle infected cell culture by RT-nested PCR (RT-N PCR) and
Southern blot (SB) analysis. The P1/T1 and P2/T2 represents the number of passage of HCV infection and treatment.
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since a fairly high-level expression of IFNAR1 and
IFNAR2 protein were detectable by Western blot and
flow analysis. In a previous study, we reported that R-
Con-15, R-Con-17 and R-Con-24 series cells have sub-
stantially reduced the expression level of Tyk2 and Jak1
levels (5). Using complementation experiments we
found that over-expression of Jak1 and Tyk2 in these
resistant cell lines did not improve the ISRE-luciferase
activity and Jak-Stat signaling. These results suggest that
the reduced expression of Jak1 and Tyk2 kinases is not
the only cause of defective Jak-Stat signaling. Therefore,
the roles of other IFN-a signaling proteins in the
mechanism of defective Jak-Stat signaling were further
investigated. Through complementation experiments, we
learned that expression of wild type IFNAR1 alone in
the resistant Huh-7 cells overcame defective Jak-Stat sig-
naling in all IFN-a resistant cells lines. The defective
Jak-Stat signaling and IFN-a resistance is related to the
defective nature of IFNAR1 protein. Stable expression of
IFNAR1 overcame the down stream Jak-Stat signaling as
well as the antiviral response against HCV in cell cul-
ture. The defective expression of IFNAR1 in the resis-
tant Huh-7 cells was confirmed by DNA sequence
analysis. Based on these results, we propose a model
(Figure 12) that explains how the amino acid deletions
in the extracellular sub-domains of IFNAR1 protein
results in alteration of receptor-ligand interactions and
subsequent inactivation of tyrosine kinases (Jak1 and
Tyk2). This event will affect the phosphorylation of Stat
proteins leading to the creation of defective down-
Figure 11 HCV infection down-regulate IFNAR1 and induces defective Jak-Stat signaling through ER-stress mechanisms. (A) Cured S-5/
15 Huh-7 cells were infected with cell culture derived HCV. Infected and uninfected cells were collected at different time points (0 to 96 hrs)
and examined for mature form of IFNAR1 protein by Western blot analysis. (B) The cellular expression of IFNAR1 in the uninfected and infected
Huh-7 cells was examined by Flow analysis at different time (0 to 240 hrs). The percentage of positive cells at each time point indicates the cells
having the IFNAR1 expression. The peak shifts with time. (C) The phosphorylation of Stat1 and Stat2 protein in the HCV transfected Huh-7 cells
was examined by Western blot analysis. The cells were treated with IFN-a for 30 minutes prior to lysis for detection of phosphoproteins. The
beta actin in all the blots was used as loading control. (D) Jak-Stat signaling of HCV transfected Huh-7 cells was examined at different time
points using a Firefly Luciferase activity of interferon-beta promoter. (E) HCV replicating Huh-7 cells were collected at different time intervals (0
to 96 hrs), protein extracts were examined for the activation of ER-stress response using panel of monoclonal and polyclonal antibodies to IRE1-
a, Bip, PERK and phospho EIF2-a. Beta actin level were measured to assure, that equal amounts of proteins were loaded onto the SDS-PAGE gel
are used in the Western blotting.
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stream Jak-Stat signaling in resistant replicon cell lines.
Dysregulation of Stat3 signaling has been linked to can-
cer development [23]. There is evidence suggesting a
high incidence of hepatocellular carcinoma in chroni-
cally infected HCV patients that are non-responders to
interferon therapy [24,25]. The results of our study
revealed that Stat3 phosphorylation and nuclear translo-
cation are also blocked in the IFN-a resistant replicon
cell line. We also noticed that the IL-6 mediated Stat3
phosphorylation is stronger in cells stably expressing
IFNAR1. The significance of Stat3 phosphorylation by
IFN-a and IL-6 should be investigated further because
the deregulated Stat3 signaling has been linked to a
number of cellular events including cellular differentia-
tion, proliferation and survival as well as immune func-
tion. The impaired Stat3 phosphorylation and nuclear
translocation in the Huh-7 cells with defective Jak-Stat
signaling may be an important cellular event in the
pathogenesis of chronic HCV infection. The replicon
based cell culture experiments established that the trun-
cation in the SD1 and SD4 region of the IFNAR1 pro-
tein prevented its association with receptor associated
Tyk2 kinase leading to the impaired Stat1 and Stat2
phosphorylation and interferon stimulating gene (ISG)
expression that resulted in the impaired antiviral state in
the resistant Huh-7 cell culture.
Figure 12 Schematic diagram summarizing the amino acid deletion of extracellular domain of IFNAR1 protein found in the IFN-a
resistant Huh-7 cells. Left panel: Four extracellular domains of IFNAR1 in the sensitive cell line with no deletion. Middle panel: 58 amino acid
deletions in the SD1 domain in the R-15 and R-24 series clones. Right panel: 50 amino acid deletions in the SD-4 domain of the R-17 series
clones. The three series of cell lines demonstrate different variants of IFNAR1 and how the signaling is blocked due to the deletion of
extracellular domains of IFNAR1.
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Since we could not find any evidence for the contribu-
tion of viral factors in the mechanisms of IFN-a resis-
tance in the replicon based cell culture, the interferon
resistance mechanism was further examined using a
transfected and/or infected full-length HCV cell culture
model. We found that HCV infected cells are relatively
resistant to IFN-a. The replication of HCV in the
infected Huh-7 cells was not inhibited even after using a
high dose of IFN-a. This is consistent with the fact as
described in many clinical studies, IFN-monotherapy
has been reported to be largely ineffective [26,27]. Here
we showed that HCV infection directly modulated the
IFNAR1 expression and induced defective Jak-Stat sig-
naling in the cell culture model. We provide evidence
that the resistant mechanism of the infectious cell cul-
ture also targets the cell surface expression of IFNAR1.
Our findings are in agreement with a report of Liu et al
[20] who demonstarted that HCV induced UPR and
down regulates the cell surface expression of IFNAR1 in
PERK-dependent manner. The mechanisms of down
regulation of IFNAR1 in the HCV replicating cells were
suggested to be due to the phosphorylation-dependent
ubiquitination and degradation of IFNAR1.
The contribution of IFNAR1 expression in the devel-
opment of defective Jak-Stat signaling and IFN-a resis-
tance is now supported by our study along with studies
conducted in the laboratory of Nabuyuki Kato [28].
These investigators have also isolated IFN-a resistant
Huh-7 based replicon cell lines and demonstrated that
cellular factors, particularly functional inactivation of
IFNAR1 rather than viral factors contributed to a highly
IFN-a resistant phenotype. The authors found nonsense
mutations and deletions in type I IFN receptor genes
(IFNAR1 and IFNAR2c) in replicon cells showing a
highly IFN-a/b resistant phenotype. A number of clini-
cal studies have also been published during recent years
where the role of IFNAR1 expression has been corre-
lated with the response to IFN-a therapy in chronic
hepatitis C. The studies conducted by Taniguchi et al.,
[29] indicated that high intrahepatic mRNA levels of
IFNAR1 and the ratio of IFNAR1 to IFNAR2 were sig-
nificantly higher in patients having a sustained viral
response (SVR) to IFN-a therapy. Another study by Kat-
sumi et al., [30] investigated whether the IFN receptor
gene expression (IFNAR1 and IFNAR2 mRNA) in the
liver could predict the long-term response to therapy in
patients with genotype 2a and 2b HCV infection. These
investigators found that the expression rate of IFNAR1
and IFNAR2 were significantly higher in responders
than non-responders. Fujiwara et al [31] have conducted
a study where the expression of IFNAR1 receptor and
response to interferon therapy was examined in chronic
hepatitis C patients. They found that the IFNAR2
expression level in the liver not in the PBMC is
predictive of the response to IFN-a treatment in chronic
hepatitis C patients. A study by Meng et al., [32] also
examined the expression of IFN-a and b receptor in the
liver of patients with a hepatitis C virus related chronic
liver disease between patients with IFN responders and
nonresponders. In this study, the authors found that the
expression of the interferon receptor was more obvious
in the IFN-a treatment responsive group than in the
non-responsive group. Welzel et al., [33] have analyzed
the relationship between variants in the IFN-a pathway
and SVR among participants in the hepatitis C antiviral
long-term treatment against the cirrhosis (HALT-C)
trial. They found statistical significance in the IFNAR1
expression and that the IFNAR2 expression is associated
with a response to antiviral therapy of chronic HCV
patients. These studies, along with our own, have now
provided evidence regarding the role of IFN-a induced
Jak-Stat pathway contribution to the acquisition of IFN-
a resistance in chronic hepatitis C. The replicon based
cell culture model used here lacks the structural genes
of HCV. Using the HCV JFH1-GFP full-length infectious
cell culture model, we have found that cells having full-
length HCV replication also develop defective Jak-Stat
signaling by downregulating cell surface expression of
the IFNAR1. In summary, these results of HCV cell cul-
ture studies using Huh-7 cells suggests that defective
expression of IFNAR1 of the Jak-Stat signaling of inter-
feron could lead to the development of HCV resistance
to IFN-a treatment. The significance of the results of
this cell culture study needs to be validated in chroni-
cally HCV infected liver disease patients who are non-
responders to IFN-a and to understand the importance
of Jak-Stat signaling in the cellular response to IFN
treatment.
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